Efficacy and visual prognostic factors of intravitreal bevacizumab as needed for macular edema secondary to central retinal vein occlusion

Figures & data

Table 1 Summary of the patients

Number of eyes (cases, N)	28 (27)
Right eye (n) %	20 (71.4%)
Males (n) %	16 (59.2%)
Mean age (years) (±SD)	66.3 (±13.5)
Duration from the onset to IVB (months)	4.6 (±5.8) (range: 0.5–27)
Baseline BCVA (logMAR) (±SD)	0.71 (±0.44)
Baseline CRT (μm) (±SD)	603 (±183)
Previous treatment (n) (%)	10 (35.7%)
Duration from previous treatment to IVB (months)	5.3 (±4.2) (range: 2–15)
Ischemic type (NPA $10 disk area) (%)	4 (14.3%)
Inner retinal fluid (n) (%)	22 (78.6%)
Outer retinal fluid (n) (%)	24 (85.7%)
Subretinal fluid (n) (%)	13 (46.4%)
Hypertension (n) (%)	18 (64.3%)
Diabetes mellitus (n) (%)	6 (21.4%)

Abbreviations: IVB, intravitreal bevacizumab; BCVA, best-corrected visual acuity; CRT, central retinal thickness; logMAR, logarithm of minimum angle of resolution; NPA, nonperfusion area; SD, standard deviation.

Figure 1 Time course of the mean BCVA and CRT from baseline in CRVO patients with IVB treatments.

Notes: Time course of (A) BCVA (logMAR) and (B) CRT.
Abbreviations: BCVA, best-corrected visual acuity; CRT, central retinal thickness; CRVO, central retinal vein occlusion; IVB, intravitreal bevacizumab; logMAR, logarithm of minimum angle of resolution.

Figure 2 Chronological alterations in the distribution of visual acuity changes in CRVO patients with IVB treatments.

Notes: The proportions of eyes in which BCVA improved more than 0.3 logMAR, changed within 0.3 logMAR, and deteriorated more than 0.3 logMAR from baseline to 1, 3, and 6 months posttreatment. The number of eyes is indicated in each bar.
Abbreviations: BCVA, best-corrected visual acuity; CRVO, central retinal vein occlusion; IVB, intravitreal bevacizumab; logMAR, logarithm of minimum angle of resolution.

Table 2 Changes in BCVA and CRT from baseline with IVB treatment

	1 month	P*	3 months	P*	6 months	P*
Change in BCVA	−0.097±0.24	0.011	−0.14±0.28	0.0049	−0.25±0.25	0.0001
Change in CRT	−250.4±171.3	<0.0001	−150.0±208.1	0.0005	−187.2±198.4	0.0002

Note:

* Wilcoxon signed rank test (comparison with baseline).

Abbreviations: BCVA, best-corrected visual acuity (logMAR); CRT, central retinal thickness; IVB, intravitreal bevacizumab; logMAR, logarithm of minimum angle of resolution.

Table 3 Factors that showed some trend toward significant association (P-value <0.2) in the univariate logistic model

Factors	OR	95% CI	P
Duration from onset to treatment (months)	0.62	0.38–0.99	0.047
Baseline BCVA (logMAR)	0.08	0.004–1.5	0.10
Presence of prior treatment (yes =1, no =0)	4.0	0.68–23.4	0.12
Systemic hypertension (yes =1, no =0)	5.7	0.59–55.6	0.13
Pretreatment macular edema (yes =1, no =0)	0.29	0.045–1.9	0.20

Abbreviations: OR, odds ratio; CI, confidence interval; BCVA, best-corrected visual acuity; logMAR, logarithm of minimum angle of resolution.